Skip to main content

Clinical trial PEARLS

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Cancers
Organ NSCLC
Trial status Trial closed for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 3
Academic trial Non
Sponsor Merck
EudraCT Identifier 2015-000575-27
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02504372
Inclusion criteria Adjuvant. ECOG 0 or 1
Last update